tbuckley/cabot-search huggingface dataset:
Assessment of the Risk of Psychiatric Disorders, Use of Psychiatric Hospitals, and Receipt of Psychiatric Medication Among Patients With Lyme Neuroborreliosis in Denmark
Authors: Malte M. Tetens, Rasmus Haahr, Ram B. Dessau, Karen A. Krogfelt, Jacob Bodilsen, Nanna S. Andersen, Jens K. Møller, Casper Roed, Claus B. Christiansen, Svend Ellermann-Eriksen, Jette M. Bangsborg, Klaus Hansen, Christian Ø. Andersen, Anne-Mette Lebech, Niels Obel, Lars H. Omland
Journal: JAMA Psychiatry (2020)

The association of Lyme neuroborreliosis with the development of psychiatric disease is unknown and remains a subject of debate.To investigate the risk of psychiatric disease, the percentage of psychiatric hospital inpatient and outpatient contacts, and the receipt of prescribed psychiatric medications among patients with Lyme neuroborreliosis compared with individuals in a matched comparison cohort.This nationwide population-based matched cohort study included all residents of Denmark who received a positive result on an intrathecal antibody index test for Borrelia burgdorferi (patient cohort) between January 1, 1995, and December 31, 2015. Patients were matched by age and sex to a comparison cohort of individuals without Lyme neuroborreliosis from the general population of Denmark. Data were analyzed from February 2019 to March 2020.Diagnosis of Lyme neuroborreliosis, defined as a positive result on an intrathecal antibody index test for B burgdorferi.The 0- to 15-year hazard ratios for the assignment of psychiatric diagnostic codes, the difference in the percentage of psychiatric inpatient and outpatient hospital contacts, and the difference in the percentage of prescribed psychiatric medications received among the patient cohort vs the comparison cohort.Among 2897 patients with Lyme neuroborreliosis (1646 men [56.8%]) and 28 970 individuals in the matched comparison cohort (16 460 men [56.8%]), the median age was 45.7 years (interquartile range [IQR], 11.5-62.0 years) for both groups. The risk of a psychiatric disease diagnosis and the percentage of hospital contacts for psychiatric disease were not higher among patients with Lyme neuroborreliosis compared with individuals in the comparison cohort. A higher percentage of patients with Lyme neuroborreliosis compared with individuals in the comparison cohort received anxiolytic (7.2% vs 4.7%; difference, 2.6%; 95% CI, 1.6%-3.5%), hypnotic and sedative (11.0% vs 5.3%; difference, 5.7%; 95% CI, 4.5%-6.8%), and antidepressant (11.4% vs 6.0%; difference, 5.4%; 95% CI, 4.3%-6.6%) medications within the first year after diagnosis, after which the receipt of psychiatric medication returned to the same level as the comparison cohort.In this population-based matched cohort study, patients with Lyme neuroborreliosis did not have an increased risk of developing psychiatric diseases that required hospital care or treatment with prescription medication. The increased receipt of psychiatric medication among patients with Lyme neuroborreliosis within the first year after diagnosis, but not thereafter, suggests that most symptoms associated with the diagnosis subside within a short period.
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
Authors: Nick van Dijk, Alberto Gil-Jimenez, Karina Silina, Kees Hendricksen, Laura A. Smit, Jeantine M. de Feijter, Maurits L. van Montfoort, Charlotte van Rooijen, Dennis Peters, Annegien Broeks, Henk G. van der Poel, Annemarie Bruining, Yoni Lubeck, Karolina Sikorska, Thierry N. Boellaard, Pia Kvistborg, Daniel J. Vis, Erik Hooijberg, Ton N. Schumacher, Maries van den Broek, Lodewyk F. A. Wessels, Christian U. Blank, Bas W. van Rhijn, Michiel S. van der Heijden
Journal: Nature Medicine (2020)
Readiness of health care systems to generate RWE: Frequency of radiographic imaging of metastatic disease during first-line systemic therapy.
Authors: Brandon Chan, David Cameron, Aria Shokoohi, Dean Regier, Howard John Lim, Cheryl Ho
Journal: Journal of Clinical Oncology (2020)

268 Background: Regulatory and Health Technology Assessment (HTA) agencies are increasingly using real world data (RWD) to support real world evidence (RWE), but the readiness of healthcare systems to reliably generate RWE is unknown. As a quality assurance measure we examined the preparedness of a single payer system to provide RWE by evaluating the frequency of CT imaging during standard first line metastatic systemic treatment of breast, colorectal (CRC) and lung cancer. Methods: A 1-year cohort of de novo metastatic breast, CRC, lung cancer patients treated with first line systemic therapy (excluding hormone therapy) referred to BC Cancer in 2016 was retrospectively reviewed. Duration of first line treatment was calculated from first to last dose of therapy. Baseline CT included imaging within 8 weeks prior to and 3 weeks after treatment initiation (first cycle). Last CT included imaging up to 8 weeks after the last dose of therapy. Results: A cohort of 675 patients was identified from the BC Cancer Registry. The distribution of de novo metastatic disease at diagnosis was lung (n = 379), CRC (n = 214) followed by breast cancer (n = 82). Conclusions: In our publicly funded health care system, baseline CT scans within 4 weeks prior to treatment ranged from 57-72%. The median CT imaging interval during first line metastatic treatment was ranged from 7.9-11.3 weeks. RWD from routine clinical practice differs significantly from clinical trials, the gold standard for regulatory and HTA assessments. Population-based data may contribute to RWE with caution due to limitations imposed by clinical practice. [Table: see text]
Quality and Safety in Health Care, Part LXXX: The National Database for Nursing Quality Indicators and the Practice Environment Scale of the Nursing Work Index.
Authors: Jay A Harolds, Laura B Miller
Journal: Clinical Nuclear Medicine (2020)

The National Database for Nursing Quality Indicators is an important source of information used to benchmark nursing by unit category in multiple areas related to not only structure and process but also outcome. It also provides some information regarding best practices and the cost to achieve certain results. The Practice Environment Scale of the Nursing Work Index is a frequently used way to measure the professional practice environment of nurses and the relationship of the latter to quality, safety, and other outcomes.
An Unusual Case of Maxillary Sinus Cholesterol Granuloma Showing FDG Uptake on PET/CT
Authors: Naoki Umeda, Masaki Hayama, Akiko Nakamura, Yohei Maeda, Hidenori Inohara
Journal: Clinical Nuclear Medicine (2020)

Abstract Cholesterol granuloma (CG) occurs primarily in the middle ear and rarely in the paranasal sinus. We report an unusual case of paranasal sinus CG with 18 F-FDG uptake. A 76-year-old man presented with right refractory epistaxis. PET/CT showed FDG uptake in the maxillary sinus. CT findings are typically uncharacteristic, whereas MRI scans are characterized by a high signal on both T1-weighted and T2-weighted images. Nasal endoscopy from the ostium revealed a granulomatous lesion with hemorrhage at the base of the maxillary sinus. After pathological examination by endoscopic sinus surgery, the patient was diagnosed with CG.
Primary Intestinal Lymphangiectasia
Authors: Pierre Pascal, Julie Malloizel, Olivier Lairez, Marie Danjoux de Volontat, Barbara Bournet
Journal: Clinical Nuclear Medicine (2020)

Primary intestinal lymphangiectasia is an unusual cause of protein losing enteropathy due to either congenital malformation or obstruction of lymphatics of intestine. The disease can affect all or only a small part of the small intestine. Peripheral lymphedema may be associated. The diagnosis is based on endoscopic and histopathological findings. A 30-year-old woman presents lower extremity edema with hypoproteinemia, hypoalbuminemia, and hypogammaglobulinemia. Tc-labeled human serum albumin nanocolloid lymphoscintigraphy of the lower extremity demonstrated a dermal backflow in the right extremity consistent with lymphedema and an unusual ileal uptake on SPECT/CT. Diagnosis is confirmed on histopathological evaluation of biopsy of ileum.
Oncology treatments during COVID-19 pandemic in Israel: ONCOR study.
Authors: Ido Wolf, Galit Hirsh-Yechezkel, Angela Chetrit, Sivan Ben-Avraham
Journal: Journal of Clinical Oncology (2020)

50 Background: The SARS-CoV-2 pandemic outbreak declared by the World Health Organization in March 2020 challenged health systems in affected countries and raised concerns for its potential direct and indirect impact on cancer patients. Cancer patients are at high risk for COVID-19 infections and complications due to factors related to their underlying condition and treatments. We aimed to evaluate the impact of COVID-19 on clinical activity of the oncology departments in Israel, and to assess the implementation of measures aimed at containment of COVID-19 diffusion, while allowing continuation of quality cancer care. Methods: A national survey among 18 of 19 oncology departments in Israel was conducted on April 2020 focusing on the institute's preparedness for treatment of their cancer patients during the COVID-19 pandemic. Results: Prevention measures against COVID-19 spread were taken prior to patients' arrival and at arrival or while staying at the departments. most participants reported employing a quick triage of patients and caregivers, prior to their entrance to the oncology units. Most departments limited the entrance of caregivers; one third not allowing entrance of any caregivers and more than half allowing entrance of only one caregiver. Some differences between large and small/medium sized medical centers were observed, with less strict measures taken by the smaller hospitals. Most departments implemented steps aimed at reducing unnecessary visits to the clinic. These included a shift to telephone interactions or telemedicine (78%) and switching to oral therapies, rather than intravenous ones, when possible. This approach was taken mostly by the medium/small hospitals compared to large hospitals (60% vs. 92%, p = 0.1). Conclusions: Oncology departments in Israel were able to prepare and adapt their services to guidelines and requirements related to the COVID-19 pandemic with little harm to their treatment capacity. However, some differences between large and small hospitals were noted. These findings call for either better allocation of resources in case of an epidemic.
Retraction of “Novel Bioluminescent Activatable Reporter for Src Tyrosine Kinase Activity in Living Mice”
Authors: Weibing Leng, Dezhi Li, Liang Chen, Hongwei Xia, Qiulin Tang, Baoqin Chen, Qiyong Gong, Fabao Gao, Feng Bi
Journal: Theranostics (2020)

[This retracts the article DOI: 10.7150/thno.14306.].
State-level needs for social distancing and contact tracing to contain COVID-19 in the United States
Authors: Weihsueh A. Chiu, Rebecca Fischer, Martial L. Ndeffo-Mbah
Journal: Nature Human Behaviour (2020)

Starting in mid-May 2020, many US states began relaxing social-distancing measures that were put in place to mitigate the spread of COVID-19. To evaluate the impact of relaxation of restrictions on COVID-19 dynamics and control, we developed a transmission dynamic model and calibrated it to US state-level COVID-19 cases and deaths. We used this model to evaluate the impact of social distancing, testing and contact tracing on the COVID-19 epidemic in each state. As of 22 July 2020, we found that only three states were on track to curtail their epidemic curve. Thirty-nine states and the District of Columbia may have to double their testing and/or tracing rates and/or rolling back reopening by 25%, while eight states require an even greater measure of combined testing, tracing and distancing. Increased testing and contact-tracing capacity is paramount for mitigating the recent large-scale increases in US cases and deaths. Using a US state-level Bayesian susceptible, exposed, infectious, removed (SEIR) compartmental model, the authors demonstrate that, in almost all states, doubling rates of contact tracing and testing while also rolling back reopening by 25–50% via social distancing can mitigate the resurgence of COVID-19.
Tissue banking from patients with SARS-CoV-2 (COVID-19) infection
Authors: Emily F. Higgs, Blake A. Flood, Athalia R. Pyzer, Sherin J. Rouhani, Jonathan A. Trujillo, Kyle R. Cron, Alexandra Cabanov, Jessica Fessler, Jeffrey Bloodworth, Kathleen Beavis, Kiang-Teck J. Yeo, Randy F. Sweis, Yuanyuan Zha, Thomas F. Gajewski
Journal: Clinical Cancer Research (2020)
Correspondence on ‘Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial’
Authors: Markus Bredemeier
Journal: Annals of the Rheumatic Diseases (2020)

The Safety and Efficacy of Nintedanib in Systemic Sclerosis (SENSCIS) trial,1 published in May 2019 in New England Journal of Medicine , analysed the efficacy and safety of nintedanib in the treatment of systemic sclerosis-related interstitial lung disease (SSc-ILD) over 52 weeks. A reanalysis of the safety and tolerability data was recently published in Annals of the Rheumatic Diseases .2 In both articles, we could not find information on the incidence of serious infections and serious respiratory tract infections.

Further safety results of the SENSCIS trial, using a wider time frame than the original publications (i.e., up to 100 weeks of follow-up), are accessible at ClinicalTrials.gov website since December 2019.3 In a closer look at the table …
Pandemic-Driven Posttraumatic Growth for Organizations and Individuals
Authors: Kristine Olson, Tait Shanafelt, Steve Southwick
Journal: JAMA (2020)

This Viewpoint discusses how disruptions from the coronavirus disease 2019 (COVID-19) pandemic can set the stage for beneficial personal and organizational change, and proposes steps that can be taken to catalyze the posttraumatic growth process.
High-throughput approaches for precision medicine in high-grade serous ovarian cancer
Authors: Meinusha Govindarajan, Christoph Wohlmuth, Matthew Waas, Marcus Q. Bernardini, Thomas Kislinger
Journal: Journal of Hematology & Oncology (2020)

Abstract High-grade serous carcinoma (HGSC) is the most prevalent and aggressive subtype of ovarian cancer. The large degree of clinical heterogeneity within HGSC has justified deviations from the traditional one-size-fits-all clinical management approach. However, the majority of HGSC patients still relapse with chemo-resistant cancer and eventually succumb to their disease, evidence that further work is needed to improve patient outcomes. Advancements in high-throughput technologies have enabled novel insights into biological complexity, offering a large potential for informing precision medicine efforts. Here, we review the current landscape of clinical management for HGSC and highlight applications of high-throughput biological approaches for molecular subtyping and the discovery of putative blood-based biomarkers and novel therapeutic targets. Additionally, we present recent improvements in model systems and discuss how their intersection with high-throughput platforms and technological advancements is positioned to accelerate the realization of precision medicine in HGSC.
Re: Hiten D. Patel, Farzana A. Faisal, Bruce J. Trock, et al. Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial. Eur Urol 2020;78:360–8
Authors: Amit Bansal, Anant Kumar
Journal: European Urology (2020)
Incorporating of telementoring (Project ECHO) into practice: Efficacy of Point Of Service Testing-Breast Cancer (ePOST-BC).
Authors: Lauren Elizabeth Nye, Anne O'Dea, Priyanka Sharma, Eve-Lynn Nelson, Traci McCarty, Karla Van Goethem, Eric Rush, Katie Nelson, Hope Krebill, Leigh Boehmer, Jennifer R. Klemp
Journal: Journal of Clinical Oncology (2020)

113 Background: An estimated 327,630 breast cancers (BC) will be diagnosed in the US in 2020, and as high as 14% (45,868) may be related to a hereditary cancer syndrome. Testing eligible patients in clinical practice is hindered by multiple barriers including time, available workforce, cost, lack of organizational pathways, provider knowledge, as well as health disparities. To address some of these barriers, our team provided a telementoring and process improvement intervention for cancer care programs primarily serving rural patients across Kansas and Western Missouri using Project ECHO. We aimed to improve the process surrounding access to genetic education and testing for patients with BC. Methods: Rural and community cancer care teams were invited by the Masonic Cancer Alliance, the outreach arm of the University of Kansas Cancer Center, to participate in ePOST-BC. Five 1-hour Project ECHO sessions (community building, didactic, and case-based learning) covered topics included: 1) essential elements of HCS and genetic testing, 2) guidelines for genetic testing in BC 3) enhanced understanding of risk, screening, and management including precision medicine in HCS, and 4) overcoming barriers to genetic testing and management in low resource settings. Provider and practice readiness was assessed using the Organizational Readiness for Implementing Change survey. A REDCap database was used for registration, surveys and data collection. Results: Ten practices (6 = metro; 4 = rural) participated in the telementoring sessions and five practices participated in the optional process improvement intervention. Provider and clinic interest and participation was high and readiness was varied. Improvements were identified in knowledge, readiness, and patient access to genetic education and testing. The level of engagement in process improvement was impacted by an identified champion (either MD and/or APP), organizational commitment, and motivator (i.e., accreditation standard, business development). Conclusions: Rural and community oncology providers are interested and willing to engage in telementoring to improve implementation of point of service genetic education and testing. This improves provider knowledge, readiness and implementation of testing. Demonstrating a change in testing completion for eligible patients is difficult in a community setting without intensive data collection. Next steps include the incorporation of technology and standardized tools into practice to address provider and care team burden.
Barriers to Virtual Video Connect (VVC)cancer care among southern rural veterans during theCOVID19 pandemic
Authors: Philip A. Haddad, Dalia Hammoud, Michelle Phelan, Rosline Wallace-Seamster, Kevin Gallagher
Journal: Clinical Cancer Research (2020)

Background: In response to COVID-19, the Department of Veterans Affairs (VA) adopted social distancing to slowthe spread of the virus and minimize the risk of viral transmission to its high-risk patients  To help protect veteransand VA providers while ensuring that veterans continue to receive high-quality care, the VA embraced telehealthplatforms such as VVC, where the provider conducts a real-time video visit through a secure connection to thepatients' computer, smart phone, or e-pad  While this platform is touted to be fast and easy, it still requires notabletechnical, skills, and knowledge components to be successful, which can be challenging in an older rural population The Hematology-Oncology service of the Overton Brooks VA Medical Center embarked on a survey to explore theacceptability and the barriers to VVC care among our cancer patients  Methodology: A phone survey of a random sample was conducted across five Hematology-Oncology clinics askingthe veterans to consent for VVC visits and, if the veteran declined, to indicate the reason behind this decision  Itspecifically asked the veteran to categorize the reason as related to Equipment, Connectivity, Literacy, Privacy, Financial, or Other/Explain  Age, sex, and race characteristics were captured for each participant  Descriptivestatistics and logistic regression were carried out  Results: The sample consisted of 101 veterans from Arkansas, Texas, and Louisiana  The median age was 71 withthe majority between ages 61-85 years  The participants were 96% male vs  4% female and 45% Black vs  55%White  Only 13% consented to VVC care  Among the veterans who declined, the reasons were related to lack of theappropriate equipment (53%), lack of adequate connection (14%), literacy (14%), and concerns with privacy (9%) No one cited financial issues  Among those who provided other reasons (10%), the majority did not see theadvantage of VVC over a regular phone call  Except for “Other,” which consisted of 78% White, the rest of thecategories' racial breakdown mirrored the whole sample  Stepwise logistic regression revealed age (p=0 03) to bethe only statistically significant factor that is inversely related to VVC acceptability  Conclusion: These results confirm our experience that the older the veteran, the less the acceptability of VVC care However, our survey indicates that 86% of the barriers to VVC use can be potentially overcome by providing theappropriate equipment along with education and training  Still, 14% of our veterans lack access to the internet  Withappropriate funding and veteran training, VVC has the potential to play a major role in rural veteran cancer careduring the COVID19 pandemic
Patient-centered communication: Collaborative learning and communication strategies for patient and healthcare providers in the new normal of COVID-19.
Authors: Martha Ann Raymond, Margaret-Ann Simonetta
Journal: Journal of Clinical Oncology (2020)

152 Background: Data from the National Cancer Institute’s Surveillance, Epidemiology &amp; End Results (SEER) program estimates in 2020 over 1.8 million new cancer diagnoses will occur. SEER data also indicates that over 15.5 million patients/survivors are currently living with a cancer diagnosis in the United States. Amid COVID-19, transitioning care beyond the clinic to minimize exposure for patients and healthcare providers is essential. Now more than ever, new and evolving ways to communicate openly and effectively are crucial for patients and their healthcare team. Methods: March-May 2020 the Raymond Foundation hosted nationwide virtual focus groups and town halls for cancer patients, survivors, and caregivers to gain a better understanding of how COVID-19 is affecting their cancer care, communication with their healthcare team, and shared decision-making. Primary goals included reaching patients in rural, urban, and community oncology settings to gain perspective from diverse populations. Results: 489 patients, survivors, and caregivers (54% female, 46% male) provided the following insights: 89% reported communication with their healthcare team had deteriorated since the pandemic; 94% indicated the need for increased communication with their healthcare team; 42% had a general knowledge of telehealth while 58% had little to no knowledge; 98% indicated they would like to learn more about telehealth options and would try this advanced class of service if offered by their healthcare team; 64% reported they were not able to accurately communicate treatment adverse effects leading to increased suffering; 96% reported increased isolation and fear of the unknown care landscape. Conclusions: Cancer patients realize the importance of patient-centered communication to facilitate a personalized dialogue to actively participate in their care. Empowering patients with the skills they require to comprehensively perceive telemedicine, virtual care, and remote monitoring will help minimize patient risk and provide an opportunity for patients to engage with their healthcare team throughout the care continuum. Implementing strategies to skillfully serve patients via telemedicine and teleconferencing may be the new normal as we virtually revive the classic house call.
COVID-19 Infection versus Influenza (Flu) and Other Respiratory Illnesses
Authors: Marianna Sockrider, Shazia Jamil, Lekshmi Santhosh, W. Graham Carlos
Journal: American Journal of Respiratory and Critical Care Medicine (2020)

"COVID-19 Infection versus Influenza (Flu) and Other Respiratory Illnesses." American Journal of Respiratory and Critical Care Medicine, 202(10), pp. P27–P28